Decreased Detection Rate of Disseminated Tumor Cells of Rectal Cancer Patients after Preoperative Chemoradiation: A First Step Towards a Molecular Surrogate Marker for Neoadjuvant Treatment in Colorectal Cancer

Annals of Surgery

Volumn 238, Issue 3, 2003, Pages 324-331

  Kienle, Peter ^a   Koch, Moritz ^a   Autschbach, Frank ^a   Benner, Axel ^b   Treiber, Martina ^a   Wannenmacher, Michael ^a   Von Knebel Doeberitz, Magnus ^a   Büchler, Markus ^a   Herfarth, Christian ^a   Weitz, Jürgen ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKERATIN; FLUOROURACIL; FOLINIC ACID; TUMOR MARKER; CYTOKERATIN 20; INTERMEDIATE FILAMENT PROTEIN; KRT20 PROTEIN, HUMAN;

ADULT; AGED; BONE MARROW; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER STAGING; COLORECTAL CANCER; CONFERENCE PAPER; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK BENEFIT ANALYSIS; ADENOCARCINOMA; ADJUVANT THERAPY; ARTICLE; CASE CONTROL STUDY; MEGAVOLTAGE RADIOTHERAPY; MIDDLE AGED; PATHOLOGY; PREOPERATIVE CARE; RECTUM TUMOR; TUMOR EMBOLISM;

ADENOCARCINOMA; BONE MARROW; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTERMEDIATE FILAMENT PROTEINS; KERATIN-20; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM CIRCULATING CELLS; PREOPERATIVE CARE; RADIOTHERAPY, HIGH-ENERGY; RECTAL NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0842332330     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Påhlmann L. Neoadjuvant and adjuvant radio- and radio-chemotherapy of rectal carcinomas. Int J Colorectal Dis. 2000;15:1-8.
2. Wheeler JD, Warren BF, Jones AC, et al. Preoperative radiotherapy for rectal cancer: implications for surgeons, pathologists and radiologists. Br J Surg. 1999;86:1108-1120.
3. Ailouni M. The role of radiation therapy in the adjuvant treatment of rectal cancer. Curr Opin Gastroenterol. 2001;17:86-90.
4. Braun S, Kentenich C, Janni W, et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol. 2000;18:80-86.
5. Pantel K, Schlimok G, Braun S, et al. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst. 1993;85:1419-1424.
6. Pantel K, von Knebel Doeberitz M. Detection and clinical relevance of micrometastatic cancer cells. Curr Opin Oncol. 2000;12:95-101.
7. Johnson P, Burchill S, Selby P. The molecular detection of circulating tumor cells. Br J Cancer, 1995;72:268-276.
8. Macfarlane DE, Dahle CE. Isolating RNA from whole blood - the dawn of RNA-based diagnosis. Nature. 1993;362:186-188.
9. Ghossein R, Bhattacharya S, Rosai J. Molecular detection of micrometastases and circulating tumor cells in solid tumors. Clin Cancer Res. 1999;5:1950-1960.
10. Weitz J, Kienle P, Lacroix J, et al. Dissemination of tumor cells in patients undergoing surgery for colorectal cancer. Clin Cancer Res. 1998;4:343-348.
11. Weitz J, Kienle P, Magener A, et al. Detection of disseminated colorectal cancer cells in lymph nodes, blood and bone marrow. Clin Cancer Res. 1999;5:1830-1836.
12. Weitz J, Koch M, Kienle P, et al. Detection of hematogenic tumor cell dissemination in patients undergoing resection of liver metastases of colorectal cancer. Ann Surg. 2000;232:66-72.
13. Koch M, Weitz J, Kienle P, et al. Comparative analysis of tumor cell dissemination in mesenteric, central and peripheral venous blood in patients with colorectal cancer. Arch Surg. 2001;136:85-89.
14. Sobin LH, Wittekind C. UICC: TNM-Classification of Malignant Tumors. London: John Wiley &cjs0038; Sons, Inc., Publications; 1997.
15. Harrell FE. Regression Modeling Strategies. New York: Springer; 2001.
16. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: John Wiley & Sons; 1989.
17. Lehmann EL. Nonparametrics: Statistical Methods Based on Ranks. San Francisco: Holden-Day, Inc.; 1975.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
19. Weber T, Lacroix J, Weitz J, et al. Expression of cytokeratin 20 in thyroid carcinomas and peripheral blood detected by reverse transcription polymerase chain reaction. Br J Cancer. 2000;82:157-160.
20. Güdemann C, Weitz J, Kienle P, et al. Detection of hematogenous micrometastasis in patients with transitional cell carcinoma. J Urol. 2000;164:532-536.
21. Glaser F, Kuntz C, Schlag P, et al. Endorectal ultrasound for control of preoperative radiotherapy of rectal cancer. Ann Surg. 1993;217:64-71.
22. Guillem JG, Puig-La Calle J, Akhurst T, et al. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum. 2000;43:18-24.
23. Luna-Perez P, Trejo-Valdivia B, Labastida S, et al. Prognostic factors in patients with locally advanced rectal adenocarcinoma treated with preoperative radiotherapy and surgery. World J Surg. 1999;23:1069-1074.
24. Janjan NA, Crane C, Feig BW, et al. Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol. 2001;24:107-112.
25. Onatis MW, Noone RB, Fields R, et al. Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival. Ann Surg Oncol. 2001;8:801-806.
26. Luna-Perez P, Segura J, Alvarado I, et al. Specific c-K-ras gene mutations as a tumor-response marker in locally advanced rectal cancer treated with preoperative chemoradiotherapy. Ann Surg Oncol. 2000;7:727-731.
27. Luna-Perez P, Arriola EL, Cuadra Y, et al. P53 protein overexpression and response to induction chemoradiation therapy in patients with locally advanced rectal adenocarcinoma. Ann Surg Oncol. 1998;5:203-208.
28. Villafranca E, Okruzhov Y, Dominguez MA, et al. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol. 2001;19:1779-1786.
29. Okonkwo A, Musunuri S, Talamonti M, et al. Molecular markers and prediction of response to chemoradiation in rectal cancer. Oncol Rep. 2001;8:497-500.
30. Allegra C. Thymidylate synthase levels: prognostic, predictive or both? J Clin Oncol. 2002;20:1711-1713.
31. Braun S, Hepp F, Kentenich C, et al. Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive cells in bone marrow. Clin Cancer Res. 1999;5:3999-4004.
32. Moll R, Löwe A, Laufer J, et al. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol. 1992;140:427-447.
33. Hawes RH. New staging techniques. Endoscopic ultrasound. Cancer. 1993;71:4187-4192.
34. Heriot AG, Grundy A, Kumar D. Preoperative staging of rectal carcinoma. Br J Surg. 1999;86:17-28.
35. Chaudhry V, Nittala M, Prasad ML. Preoperative chemoradiation and coloanal J pouch reconstruction for low rectal cancer. Am Surg. 2000;66:387-393.
36. Grann A, Feng C, Wong D, et al. Preoperative combined modality therapy for clinically resectable UT3 rectal adenocarcinoma. Int J Radiation Oncology Biol Phys. 2001;49:987-995.